Review
Cardiac & Cardiovascular Systems
Jacqueline T. Vuong, Ashley F. Stein-Merlob, Richard K. Cheng, Eric H. Yang
Summary: Anthracyclines are important in the treatment of various cancers, but can have significant implications on cardiovascular health. As the number of cancer survivors increases, it becomes crucial to detect and treat anthracycline-induced cardiotoxicity. Current treatment methods are based on conventional heart failure treatment, but there is a need for specific therapies for anthracycline-induced cardiotoxicity.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Yu-Wei Chang, Hui-Ying Weng, Shih-Feng Tsai, Frank Sheng Fan
Summary: Anthracycline-induced cardiomyopathy is a significant issue in clinical oncology. Recent advancements have been made in identifying genetic defects associated with anthracycline-induced cardiotoxicity. This case report presents preliminary findings of a genetic study on a patient who developed cardiomyopathy after receiving anthracycline-based chemotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Medicine, General & Internal
Nadine Norton, Raegan M. Weil, Pooja P. Advani
Summary: Anthracyclines, widely used in oncology, have a significant side effect of cardiotoxicity, but progress is being made in predicting high-risk individuals and developing individualized cardioprotective plans through methodology and pharmacogenetic studies.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Fabian Muehlberg, Markus Kornfeld, Leonora Zange, Saeed Ghani, Annette Reichardt, Peter Reichardt, Jeanette Schulz-Menger
Summary: This study aims to assess the subclinical changes in functional and morphologic myocardial MR parameters early in the course of high-dose anthracycline treatment. The results suggest that an early increase in myocardial T2 times 48 hours after the first anthracycline treatment may predict the subsequent development of anthracycline-induced cardiomyopathy. Additionally, a decrease in native T1 times was observed regardless of the development of cardiomyopathy in high-dose anthracycline therapy.
Article
Medicine, General & Internal
Keiko Inoue, Noriko Iida, Kazuko Tajiri, Hiroko Bando, Shigeru Chiba, Nobutaka Tasaka, Kenji Nagashio, Rumi Sasamura, Hiroyuki Naito, Momoko Murata, Siqi Li, Tomoko Ishizu, Yoko Nakazawa, Ikuo Sekine, Masaki Ieda
Summary: The study conducted a prospective multicenter registry study on cardiac management in patients treated with anthracyclines. Analysis of 1-year follow-up data of 97 patients showed the feasibility of the AIC registry study in Japanese patients. The study aims to collect echocardiographic and biomarker data on cardiotoxicity in a real-world setting.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Peng Xia, Jingrui Chen, Yadav Sapkota, Erika N. Scott, Yuening Liu, Melissa M. Hudson, Shahrad R. Rassekh, Bruce C. Carleton, Colin J. D. Ross, Eric J. Chow, Zhaokang Cheng
Summary: This study found that RBL2 is an endogenous CDK2 inhibitor in the heart, which can inhibit FOXO1-mediated pro-apoptotic gene expression. Loss of RBL2 increases sensitivity to DOX-induced cardiotoxicity. These findings suggest that RBL2 could be used as a biomarker to predict the risk of cardiotoxicity before the initiation of anthracycline-based chemotherapy.
JACC: CARDIOONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
A. C. Seara Fernando, Tais H. Kasai-Brunswick, H. M. Nascimento Jose, Antonio C. Campos-de-Carvalho
Summary: Anthracyclines are effective chemotherapeutic drugs for cancer treatment, but they can cause cardiotoxicity. Accumulation of senescent cardiac cells is an emerging mechanism associated with anthracycline-induced cardiotoxicity.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Junqi Huang, Rundong Wu, Linyi Chen, Ziqiang Yang, Daoguang Yan, Mingchuan Li
Summary: This review summarizes the recent findings on the mitochondrial mechanisms during anthracycline cardiotoxicity, including the production of ROS and mitochondrial damage, mitochondrial iron overload and ferroptosis, autophagy, mitophagy, and disruption of cardiac metabolism.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Thiago Ferreira de Souza, Thiago Quinaglia Silva, Ligia Antunes-Correa, Zsofia D. Drobni, Felipe Osorio Costa, Sergio San Juan Dertkigil, Wilson Nadruz, Facricio Brenelli, Andrei C. Sposito, Jose Roberto Matos-Souza Jr, Otavio Rizzi Coelho, Tomas G. Neilan, Michael Jerosch-Herold, Otavio Rizzi Coelho-Filho
Summary: Limited data exists on how anthracyclines affect the structure, function, and tissue characteristics of the right ventricle. This study found that breast cancer patients treated with anthracyclines experienced right ventricular atrophy, systolic dysfunction, and an increase in diffuse interstitial fibrosis, indicating a cardiotoxic response similar to that observed in the left ventricle.
SCIENTIFIC REPORTS
(2021)
Article
Cardiac & Cardiovascular Systems
Sanya Chhikara, Matthew Hooks, Pal Satyajit Singh Athwal, Andrew Hughes, Mohamed F. Ismail, Stephanie Joppa, Pratik S. Velangi, Prabhjot S. Nijjar, Anne H. Blaes, Chetan Shenoy
Summary: In cancer survivors treated with anthracycline-based chemotherapy, the prevalence of right ventricular (RV) systolic dysfunction is high, accompanied by left ventricular (LV) systolic dysfunction in almost all cases. However, RV systolic dysfunction is not independently associated with long-term outcomes.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING
(2022)
Article
Oncology
William W. Tseng, Francesco Barretta, Lorenzo Conti, Giovanni Grignani, Francesco Tolomeo, Markus Albertsmeier, Martin K. Angele, Piotr Rutkowski, Jacek Skoczylas, Antonino De Paoli, Federico Navarria, Chandrajit P. Raut, Mark Fairweather, Jeffrey M. Farma, Carolyn Nessim, Neha Goel, Valerie P. Grignol, Samuel J. Ford, Kenneth Cardona, Ty Subhawong, Hannah L. Tattersall, Rachel M. Lee, James S. Hu, Margaret von Mehren, Roberta Sanfilippo, Alessandro Gronchi
Summary: In high-risk RPS patients, the response to neoadjuvant systemic therapy is generally fair. Disease progression during therapy may be a predictor of survival post-surgery. Subtype-specific regimens should be further validated.
Article
Biochemistry & Molecular Biology
Justin S. Kim, Andres S. Arango, Swapnil Shah, William R. Arnold, Emad Tajkhorshid, Aditi Das
Summary: By using experimental and theoretical methods, this study unveils the interactions between anthracycline derivatives and CYP2J2, which helps to understand the potential mechanism of anthracycline cardiotoxicity and aids in the design of new anthracycline derivatives with lower toxicity.
JOURNAL OF INORGANIC BIOCHEMISTRY
(2022)
Article
Cardiac & Cardiovascular Systems
Carlos Galan-Arriola, Jean Paul Vilchez-Tschischke, Manuel Lobo, Gonzalo J. Lopez, Antonio De Molina-Iracheta, Claudia Perez-Martinez, Rocio Villena-Gutierrez, Alvaro Macias, Ivan A. Diaz-Rengifo, Eduardo Oliver, Valentin Fuster, Javier Sanchez-Gonzalez, Borja Ibanez
Summary: The aim of this study was to investigate the changes in coronary microcirculation status during and after repeated anthracycline treatment. The results showed that anthracycline treatment is associated with progressive and irreversible damage to the microcirculation. The damage to the microcirculation persists even in low cumulative dose regimes and may explain the increased incidence of cardiovascular events in cancer survivors who received anthracyclines without cardiac contractile defects.
CARDIOVASCULAR RESEARCH
(2022)
Review
Cardiac & Cardiovascular Systems
Talal Khalid Al-Otaibi, Benjamin Weitzman, Usman A. Tahir, Aarti Asnani
Summary: This review summarizes the evidence supporting genetic variants associated with anthracycline-associated cardiotoxicity (ACT) and discusses future directions for incorporating genetics into clinical practice.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Oncology
Wolfram C. M. Dempke, Rafal Zielinski, Christina Winkler, Sandra Silberman, Susanne Reuther, Waldemar Priebe
Summary: Anthracyclines are highly effective cytostatic drugs used in cancer treatment, but they also cause significant cardiotoxicity. The development of reactive oxygen species and inhibition of topoisomerase II beta are believed to be the key mechanisms responsible for cardiotoxicity. To prevent this, various strategies, including drug therapy and the development of non-cardiotoxic analogues, are being pursued.
EUROPEAN JOURNAL OF CANCER
(2023)